12Apr 2019

THE SIGNIFICANCE OF LABORATORY CLASSIFICATION OF ISOLATED GROWTH HORMONE DEFICIENCY.

  • Department of pediatrics, college of medicine, University of Kufa.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background:Short Stature (SS) is defined as a standing height more than 2 standard deviations (SDs) below the mean (or below the 2.5 percentile) for sex. Causes of short stature include familial short stature, constitutional delay, endocrinopathies (e.g. Growth Hormone Deficiency), chronic systemic diseases and syndromic causes of SS. Aim of the study:To show the significance of the laboratory classification of isolated GHD to help for adjustment of dosages and duration of GH treatment. Methods:A retrospective study of children with isolated Growth Hormone Deficiency (GHD) who have been registered in GH Unit in the Al-Zahraa teaching hospital for Maternity and Children at Al Najaf city, Iraq from March 2012 to September 2016. A total number of 122 patients included in this study all of them on GH replacement .The population study were classified according to post-stimulation peak serum GH level into Mild GHD (>8 − <10ng/ml ) ,Moderate GHD (≥5 − ≤ 8ng/ml) and Severe GHD (< 5ng/ml). The cases also grouped according to age into 3 age groups (Group A: < 6 years, Group B: ≥ 6 − <11 years and Group C: ≥11years), sex and residency. In each of these age groups, comparison done between Mild, Moderate and severe isolated GHD. Results:This study showed that in Group A (35 cases) there was no statistically significant difference between Mild, Moderate and Severe isolated GHD regarding pre-treatment height and rate of the height velocity after the first year of GH treatment (p-value=0.6 for pre-treatment height and 0.74 for rate of height velocity H.V.). In Group B (50 cases) and Group C (37 cases) also no statistically significant difference, Group B (p-value=0.53 for pre-treatment height and p-value= 0.92 for H.V.) and Group C (p-value=0.63 for pre-treatment height, p-value= 0.92 for H.V.) Conclusion:No significance of classification of short stature children with isolated GHD according to stimulated peak GH value with cut-off less 10 ng/ml.

  1. [Guideline] Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Pediatric Endocrinology Workshop.J Clin Endocrinal Metab. 2008 Nov. 93(11):4210-7.
  2. Nwosu BU, Lee MM. Evaluation of short and tall stature in children.Am Fam Physician. 2008;78(5):597?604.
  3. Lee, P.A., et. al.? . Persistent short stature, other outcomes, and the effect of growth hormone treatment in children who are born small for gestational age .? 2005 , 112(1), 150-162
  4. Rose, S.R., et. al.. A general pediatric approach to evaluating a short child. Pediatrics in Review, 2005 , 26(11), 410-420
  5. Lin-Su K,Wajnrajch Growth hormone releasing hormone (GHRH) and GHRH receptor.2002.Rev Endocr Metab Disord.3(4):313-314
  6. Gardner DG,Shoback .Greenspans Basic and Clinical Endocrinology .2007.pp.193-201
  7. Yi S, Bernat B, P?l G, Kossiakoff A, Li WH .Functional promiscuity of squirrel monkey growth hormone receptor toward both primate and nonprimate growth hormones .2002,?Mol.Biol.Evol.?19?(7):108392.
  8. Bartholomew EF, Martini F, Nath JL .?Fundamentals of anatomy & physiology. Upper Saddle River,2009, NJ: Pearson Education Inc. pp.?616?617
  9. Nindl BC, Hymer WC, Deaver DR, Kraemer WJ. Growth hormone pulsatility profile characteristics following acute heavy resistance exercise .2001,? Appl. Physiol.?91?(1): 163?72.
  10. Mullis, P E. Genetic control of growth.?Eur. J. Endocrinol .2005 , ?152,?11-31 ??29-?Growth Hormone Deficiency . UK Child Growth Foundation.? ?2009-01-16.
  11. Hanew K, Utsumi AEur .The role of endogenous GHRH in arginine-, insulin-, clonidine- and L-dopa-induced GH release in normal subjects. J Endocrinol. 2002 Feb; 146(2):197-202.
  12. Hilczer M, Smyczynska J, Lewinski A. Limitations of clinical utility of growth hormone stimulating tests in diagnosing children with short stature.?Endocr Regul.?2006;40:69?75.
  13. Cooke DW, Divall SA, Radovick S. Normal and aberrant growth in children. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds.Williams Textbook of Endocrinology. 2016, 13th ed. Philadelphia, PA: Elsevier Saunders;? :chap 24
  14. Keane V. Assessment of growth. In: Kliegman R, Nelson WE, eds.?Nelson Textbook of Pediatrics. 19th ed. Philadelphia, Pa.: Elsevier/Saunders; 2011.
  15. Saggese G, Ranke MB, Saenger P, Rosenfeld RG, Tanaka T, et al.??Diagnosis and treatment of growth hormone deficiency in children and adolescents; 1998, towards a consensus.?Horm Res. 50:320?340
  16. Gary Butler. Indications for growth hormone therapy. Paediatrics and Child Health 2007; 17: 9: 356-61.
  17. Daniela F.?Cardoso?, Carlos Eduardo?Martinelli?Jr.? et al.?? Comparison between the growth response to growth hormone (GH) therapy in children with partial GH insensitivity or mild GH deficiency.2014 Arq Bras Endocrinol Metab?vol.58?no.1?S?o Paulo?Feb.
  18. Smyczyńska J1,?Lewiński A,?Hilczer M,?Stawerska R,?Karasek M. Partial growth hormone deficiency (GHD) in children has more similarities to idiopathic short stature than to severe GHD.Endokrynol Pol.2007 May-Jun;58(3):182-7.
  19. Broeck Van den J, Arends N, Hokken-Koelega A: Growth response to recombinant human growth hormone (GH) in children with idiopathic growth retardation by level of maximum GH peak during GH stimulation tests. 2000, Horm Res. 53: 267-273.

[Shamil A. Sharba. (2019); THE SIGNIFICANCE OF LABORATORY CLASSIFICATION OF ISOLATED GROWTH HORMONE DEFICIENCY. Int. J. of Adv. Res. 7 (Apr). 955-960] (ISSN 2320-5407). www.journalijar.com

Shamil A. Sharba
MD

DOI:

Article DOI: 10.21474/IJAR01/8913      
DOI URL: http://dx.doi.org/10.21474/IJAR01/8913

Download Full Paper

Download PDF No. of Downloads: 6 | No. of Views: 25